Paper
Paper
Search...
Search ResearchHub...
Ctrl+K
New
Home
Browse
Earn
Fund
RH Journal
Notebook
Lists
Leaderboard
RSC
USD
Changelog
Terms
Privacy
Issues
Docs
Support
Foundation
About
990O Final results from phase I, first-in-human, dose esc... | ResearchHub
Paper
Paper
Search...
Search ResearchHub...
Ctrl+K
New
Home
Browse
Earn
Fund
RH Journal
Notebook
Lists
Leaderboard
RSC
USD
Changelog
Terms
Privacy
Issues
Docs
Support
Foundation
About
990O Final results from phase I, first-in-human, dose escalation study of a first-in-class anti-ILT2 antibody, SAR444881, alone and with pembrolizumab or cetuximab, in patients with advanced solid tumors
0
Authors
Ruth Perets
19 more
Ruth Perets
•
Salomon Stemmer
17 more
•
Mitesh Borad
Published
September 1, 2024
Paper
Conversation
0
Reviews
0
Bounties
0
Sign in to comment
Add a comment...
Best
Supporters
Support the authors with ResearchCoin
Tip RSC
Journal
Annals of Oncology
Topics
Medicine
Cancer Oncology
Immunology
Internal Medicine
Radiology, Nuclear Medicine And Imaging
Show all topics
DOI
10.1016/j.annonc.2024.08.1049
